StreetInsider.com News Articles

Form 8-K Aptevo Therapeutics Inc. For: Mar 10

Wed, 11 Mar 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260311/26142043.html

Form 8-K Aptevo Therapeutics Inc. For: Mar 10

Wed, 11 Mar 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260311/26142043.html

Aptevo reports 86% clinical benefit rate for AML drug mipletamig

Tue, 10 Mar 2026 08:21:59 -0400

Aptevo Therapeutics Inc. (NASDAQ: APVO) reported interim data showing its drug candidate mipletamig achieved an 86% clinical benefit rate when combined with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients who are elderly or unfit for intensive chemotherapy.

The data covers 28 evaluable frontline patients from two trials, including 24 patients from the ongoing RAINIER trial and 4 patients from a completed dose expansion trial. Among these patients, 79% achieved complete remission or complete remission with incomplete blood marker recovery, while 61% achieved complete remission.

No patients in the frontline group experienced cytokine release syndrome, a common side effect associated

Aptevo reports 86% clinical benefit rate for AML drug mipletamig

Tue, 10 Mar 2026 08:21:59 -0400

No patients in the frontline group experienced cytokine release syndrome, a common side effect associated

Aptevo reports 86% clinical benefit rate for AML drug mipletamig

Tue, 10 Mar 2026 08:21:59 -0400

No patients in the frontline group experienced cytokine release syndrome, a common side effect associated

Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

Tue, 10 Mar 2026 08:05:00 -0400

Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine

SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR^™ and ADAPTIR-FLEX^™ platform technologies, today announced new interim data for mipletamig in combination with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia (AML) patients who are either elderly or unfit for intensive chemotherapy. In data from two trials, the combination has demonstrated robust clinical activity, delivering an 86%

Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

Tue, 10 Mar 2026 08:05:00 -0400

Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine

Form 8-K Aptevo Therapeutics Inc. For: Feb 18

Thu, 19 Feb 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260219/26025285.html

Form 8-K Aptevo Therapeutics Inc. For: Feb 18

Thu, 19 Feb 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260219/26025285.html

Form SCHEDULE 13G/A Aptevo Therapeutics Inc. Filed by: Point72 Asset Management, L.P.

Tue, 17 Feb 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260217/26013558.html

Form SCHEDULE 13G/A Aptevo Therapeutics Inc. Filed by: Point72 Asset Management, L.P.

Tue, 17 Feb 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260217/26013558.html

Form SCHEDULE 13G/A Aptevo Therapeutics Inc. Filed by: CVI Investments, Inc.

Tue, 17 Feb 2026 14:46:00 -0400

si-local-file:///var/storage/secattach/20260217/26011298.html

Form SCHEDULE 13G/A Aptevo Therapeutics Inc. Filed by: CVI Investments, Inc.

Tue, 17 Feb 2026 14:46:00 -0400

si-local-file:///var/storage/secattach/20260217/26011298.html

Form 8-K Aptevo Therapeutics Inc. For: Jan 30

Tue, 03 Feb 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260203/25934784.html

Form 8-K Aptevo Therapeutics Inc. For: Jan 30

Tue, 03 Feb 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20260203/25934784.html

Aptevo Therapeutics announces CEO transition effective April

Tue, 03 Feb 2026 08:06:48 -0400

Aptevo Therapeutics Inc. (NASDAQ: APVO) announced executive leadership changes effective April 1, 2026, according to a company statement. Marvin White, who has served as President and Chief Executive Officer since 2016, will retire from his current position and assume the role of Executive Chair.

Jeff Lamothe, currently Chief Operating Officer, will become President and Chief Executive Officer and join Aptevo's Board of Directors. John E. Niederhuber, M.D., will transition from Chairman of the Board to Lead Independent Director. All three executives have been with the biotechnology company since its inception in 2016.

White stated the transition reflects a shift in leadership alignment

Aptevo Therapeutics announces CEO transition effective April

Tue, 03 Feb 2026 08:06:48 -0400

White stated the transition reflects a shift in leadership alignment

Aptevo Therapeutics announces CEO transition effective April

Tue, 03 Feb 2026 08:06:48 -0400

White stated the transition reflects a shift in leadership alignment

Aptevo Therapeutics announces CEO transition effective April

Tue, 03 Feb 2026 08:06:48 -0400

White stated the transition reflects a shift in leadership alignment

Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

Tue, 03 Feb 2026 08:05:00 -0400

Clinical progress, pipeline expansion, and operational momentum underpin leadership continuity as the Company advances into 2026 and beyond

SEATTLE, WA / ACCESS Newswire / February 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced executive leadership transitions to support the Company's continued execution, drive achievement of long-term strategic objectives, and next phase of growth.

Effective April 1, 2026, Marvin White, who has served as President and Chief Executive Officer since 2016, has chosen to retire from this

Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

Tue, 03 Feb 2026 08:05:00 -0400

Clinical progress, pipeline expansion, and operational momentum underpin leadership continuity as the Company advances into 2026 and beyond

Effective April 1, 2026, Marvin White, who has served as President and Chief Executive Officer since 2016, has chosen to retire from this

Form EFFECT Aptevo Therapeutics Inc.

Mon, 02 Feb 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260202/25926528.html

Form EFFECT Aptevo Therapeutics Inc.

Mon, 02 Feb 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260202/25926528.html

Form 424B4 Aptevo Therapeutics Inc.

Fri, 30 Jan 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260130/25924395.html

Form 424B4 Aptevo Therapeutics Inc.

Fri, 30 Jan 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260130/25924395.html